Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Isotretinoin (Primary) ; Carboplatin; Cyclophosphamide; Doxorubicin; Etoposide; Topotecan
- Indications Neuroblastoma
- Focus Biomarker; Therapeutic Use
- 06 Jul 2021 Biomarkers information updated
- 03 Aug 2012 Planned end date changed from 1 Sep 2012 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 06 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.